SCHEMBL3479573

SCHEMBL3479573

CN1CCN(c2ccc3ccccc3c2F)c2ccc(-c3ccc(=O)[nH]n3)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.40
SLC6A2 P23975 4/20 0.37
SLC6A3 Q01959 4/20 0.37
SLC6A4 P31645 3/20 0.37
CYP1A2 P05177 2/20 0.35
PDE4A P27815 3/20 0.35
PDE4B Q07343 3/20 0.35
PDE4C Q08493 3/20 0.35
PDE4D Q08499 3/20 0.35
GPR119 Q8TDV5 1/20 0.35
HRH3 Q9Y5N1 5/20 0.35
LMNA P02545 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PDE3B Q13370 3/20 0.34
PDE3A Q14432 3/20 0.34
TP53 P04637 2/20 0.33
MAPK1 P28482 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479731 0.85 SCN9A (0.43) SCN9ASLC6A2SLC6A3SLC6A4CYP1A2
SCHEMBL3234151 0.84 SCN9A (0.46) SCN9ASLC6A2SLC6A3SLC6A4CYP1A2
SCHEMBL3479716 0.82 SCN9A (0.47) SCN9ASLC6A2SLC6A3SLC6A4CYP1A2
SCHEMBL3217462 0.82 SCN9A (0.40) SCN9ASLC6A2SLC6A3SLC6A4SMN1; SMN2
SCHEMBL3479683 0.81 SCN9A (0.38) SCN9ACYP1A2CYP1A1CYP1B1TNKS
SCHEMBL3479414 0.81 SCN9A (0.46) SCN9ASLC6A2SLC6A3SLC6A4PDE4A
SCHEMBL3479922 0.81 SCN9A (0.44) SCN9ASLC6A2SLC6A3SLC6A4CYP1A2
SCHEMBL3479740 0.80 SLC6A2 (0.48) SCN9ASLC6A2SLC6A3SLC6A4
SCHEMBL3479997 0.79 SCN9A (0.38) SCN9ASMN1; SMN2HTR3AALDH1A1
SCHEMBL3479404 0.79 SLC6A2 (0.47) SCN9ASLC6A2SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885SLC6A2 28/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.